Trial register facet
Trial records for Retatrutide
28 records for Retatrutide, of which 7 are published trials.
Showing 0 records on this page
Records
28 documents · page 1 of 2
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| RETA-PH2-OBESITY | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 338 | 2023 | Moderate |
| RETA-PH2-T2D | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 281 | 2023 | Moderate |
| RETA-PH2-OBESITY-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-OBESITY-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-T2D-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| TRIUMPH-1 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-2 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-3 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-4 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-OSA | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-1-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| TRIUMPH-2-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-3-OLEprogramme record | Retatrutide | Phase 3 | Ongoing | Single-arm open-label | — | — | Very low |
| TRIUMPH-4-BODY-COMPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-OSA-OLEprogramme record | Retatrutide | Phase 3 | Ongoing | Single-arm open-label | — | — | Very low |
| TRIUMPH-1-PKprogramme record | Retatrutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| TRIUMPH-2-QOLprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-4-REGIONAL-JPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
page 1 of 2